- Home
- HCM vs IOVA Comparison
HCM vs IOVA Comparison
Compare HCM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- IOVA
- Stock Information
- Founded
- HCM 2000
- IOVA 2007
- Country
- HCM Hong Kong
- IOVA United States
- Employees
- HCM N/A
- IOVA N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCM Health Care
- IOVA Health Care
- Exchange
- HCM Nasdaq
- IOVA Nasdaq
- Market Cap
- HCM 2.6B
- IOVA 2.6B
- IPO Year
- HCM N/A
- IOVA N/A
- Fundamental
- Price
- HCM $14.20
- IOVA $5.91
- Analyst Decision
- HCM Hold
- IOVA Strong Buy
- Analyst Count
- HCM 1
- IOVA 9
- Target Price
- HCM $19.00
- IOVA $23.33
- AVG Volume (30 Days)
- HCM 76.1K
- IOVA 9.0M
- Earning Date
- HCM 02-26-2025
- IOVA 02-26-2025
- Dividend Yield
- HCM N/A
- IOVA N/A
- EPS Growth
- HCM N/A
- IOVA N/A
- EPS
- HCM N/A
- IOVA N/A
- Revenue
- HCM $610,806,000.00
- IOVA $90,858,000.00
- Revenue This Year
- HCM N/A
- IOVA $13,758.71
- Revenue Next Year
- HCM $20.69
- IOVA $171.20
- P/E Ratio
- HCM N/A
- IOVA N/A
- Revenue Growth
- HCM N/A
- IOVA 12751.20
- 52 Week Low
- HCM $11.93
- IOVA $5.62
- 52 Week High
- HCM $21.92
- IOVA $18.33
- Technical
- Relative Strength Index (RSI)
- HCM 42.32
- IOVA 28.87
- Support Level
- HCM $13.00
- IOVA $5.62
- Resistance Level
- HCM $15.29
- IOVA $6.44
- Average True Range (ATR)
- HCM 0.46
- IOVA 0.45
- MACD
- HCM -0.00
- IOVA -0.10
- Stochastic Oscillator
- HCM 37.74
- IOVA 11.46
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.